Stocklytics Platform
Asset logo for symbol GLSI
Greenwich LifeSciences
GLSI37
$9.74arrow_drop_down0.61%-$0.06
Asset logo for symbol GLSI
GLSI37

$9.74

arrow_drop_down0.61%
no data available for key stats

There's no data available for key stats

no data available for ratios/profitability stats

There's no data available for ratios/profitability stats

Fundamentals
Gross Profit-
Payout Ratio-
Industry average yield2.89%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

—Strong Buy
—Buy
—Neutral
—Sell
—Strong Sell

Analyst rating

An aggregate view of professional's ratings.

—Strong Buy
—Buy
—Neutral
—Sell
—Strong Sell

Stock Performance

GLSI-
US Healthcare Sector-
US Market-
warning

GLSI / Market

GLSI lose to the US Market which returned 0.03% over the last twenty four hours.
warning

GLSI / Healthcare Sector

GLSI lose to the US Healthcare sector which returned 2.60% over the last twenty four hours.

Greenwich LifeSciences (GLSI) Statistics

Greenwich LifeSciences, Inc. (GLSI) is a biotechnology company focused on the development of targeted immunotherapy for the prevention of breast cancer recurrence. The company's lead product candidate, GP2, is a peptide vaccine designed to stimulate an immune response against HER2/neu, a protein that is overexpressed in breast cancer cells. GP2 is administered in combination with a standard-of-care therapy called granulocyte macrophage-colony stimulating factor (GM-CSF), which helps to enhance the immune response. GLSI is currently conducting a Phase III clinical trial for GP2, with results expected in 2022.
In terms of valuation metrics, GLSI has a market capitalization of approximately $200 million as of the latest available data. The company's stock price has experienced significant volatility in recent years, reaching a high of over $100 per share in 2020 before dropping to current levels around $10. GLSI's stock performance has also been influenced by trends in the broader biotechnology sector, as well as news and developments related to the company's clinical trials and pipeline of product candidates.
add Greenwich LifeSciences to watchlist

Keep an eye on Greenwich LifeSciences

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

How has Greenwich LifeSciences (GLSI) stock's performance compared to its sector and the market over the past year?

Over the past year, Greenwich LifeSciences (GLSI) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 15.12%, Greenwich LifeSciences has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 23.87%, it has fallen short of the market average. This comparison highlights Greenwich LifeSciences's performance relative to both its sector and the overall market over the last year.
help

What is the PE ratio of Greenwich LifeSciences (GLSI) stock?

The PE ratio for Greenwich LifeSciences (GLSI) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.
help

What is the EPS of Greenwich LifeSciences (GLSI) stock?

The Earnings Per Share (EPS) for Greenwich LifeSciences (GLSI), calculated on a diluted basis, is -$0.81. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help

What is the operating margin of Greenwich LifeSciences (GLSI) stock?

The operating margin for Greenwich LifeSciences (GLSI) is 0%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help

What is the EBITDA of Greenwich LifeSciences (GLSI) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Greenwich LifeSciences (GLSI) is -$10.76M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.
help

How much debt does Greenwich LifeSciences (GLSI) have?

Greenwich LifeSciences (GLSI) has a total debt of $0. The net debt, which accounts for cash and cash equivalents against the total debt, is -$5.82M.

Take Your Investments to a Whole New Level